Sara Kenkare-Mitra
Alector (United States)(US)
Publications by Year
Research Areas
Neuroinflammation and Neurodegeneration Mechanisms, Inflammation biomarkers and pathways, Alzheimer's disease research and treatments, Neurological Disease Mechanisms and Treatments, Amyotrophic Lateral Sclerosis Research
Most-Cited Works
- → Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate(2008)1,659 cited
- → Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease(2024)74 cited
- → Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors(2009)30 cited
- → Targeting Progranulin as an Immuno-Neurology Therapeutic Approach(2023)16 cited
- → The Alzheimer’s Disease Risk Genes MS4A4A And MS4A6A Cooperate to Negatively Regulate Trem2 and Microglia states(2024)6 cited
- → Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s disease(2025)2 cited
- → Integrative analysis of pooled CRISPR screens provide functional insights into AD GWAS risk genes(2025)1 cited
- → The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial(2026)
- → The Alzheimer's Disease Risk Genes MS4A4A and MS4A6A Cooperate to Negatively Regulate TREM2 and Microglia States(2025)